Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jazz Wades Into Cannabinoid Weeds With $7.2bn GW Buy

Epilepsy Drug Epidiolex Adds To Sleep, Oncology Franchises

Executive Summary

Priced at a 50% premium to GW’s value, the deal will reduce the percentage of Jazz’s drug sales coming from Xyrem, provide double-digit revenue growth and expand the R&D pipeline to 19 programs.

You may also be interested in...



Hopes For A ‘New Era’ In UK Biotech Financing With Pension-Backed Fund

Backed by the UK government and the Phoenix Group, the initial £200m fund is aimed at convincing pension funds to invest in the higher-risk, higher-reward life sciences sector.

Autifony Tunes In To Jazz With Neurology-Focused Deal

Deal Snapshot: The two companies will collaborate on drugs targeting two ion channels in neurological disorders, with Autifony receiving upfront and milestone payments up to $770.5m.

Jazz Pins Sativex US Hopes On Two Advanced Studies After First MS Spasticity Trial Flunks

The Irish firm’s cannabis-derived nabiximols spray missed the primary endpoint in a late-stage multiple sclerosis spasticity trial, but it is unfazed as hopes remain for two ongoing spasticity studies.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC143755

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel